Skip to main content

Table 5 Clinical outcome and length of treatment in TDM and non-TDM groups, further separated by presence or absence of renal impairment (RI or non-RI groups)

From: Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients

Total TDM group, n = 56 (47.5%) Non-TDM group, n = 62 (52.5%) P-value
Recovery, n (%) 38 (67.9) 35 (56.5) 0.26
Duration of linezolid treatment (days), median (IQR) 30 (19.5–45) 12 (9–21.3) < 0.0001
Failure, n (%) 14 (25.0) 27 (43.6) 0.052
Failure due to persistence of infection, n (%) 6 (10.7) 2 (3.2) 0.15
Failure due to hematological toxicity, n (%) 10 (17.9) 18 (29.0) 0.20
Failure due to other toxicity, n (%) 3 (5.4) 8 (12.9) 0.21
Thirty-day reinfection, n (%) 5 (8.9) 4 (6.5) 0.73
Thrombocytopenia 32 (66.7) 16 (33.3) 0.0007
RI group TDM group, n = 21, (60.0%) Non-TDM group, n = 14, (40.0%) P-value
Recovery, n (%) 15 (71.4) 5 (35.7) 0.080
Duration of linezolid treatment (days), median (IQR) 34 (20–46) 11.5 (8.8–13.3) < 0.0001
Failure, n (%) 3 (14.3) 9 (64.3) 0.0038
Failure due to persistence of infection, n (%) 1 (4.8) 0 (0.0) 1.00
Failure due to hematological toxicity, n (%) 2 (9.5) 8 (57.1) 0.0056
Failure due to other toxicity, n (%) 0 (0.0) 2 (14.3) 0.15
Thirty-day reinfection, n (%) 3 (14.3) 1 (7.1) 0.64
Thrombocytopenia 17 (81.0) 5 (35.7) 0.012
Non-RI group TDM group, n = 35 (42.2%) Non-TDM group, n = 48 (57.8%) P-value
Recovery, n (%) 23 (65.7) 30 (62.5) 0.82
Duration of linezolid treatment (days), median (IQR) 29 (19–45) 13.5 (9–22.8) < 0.0001
Failure, n (%) 18 (37.5) 11 (31.4) 0.64
Failure due to persistence of infection, n (%) 2 (4.2) 5 (14.3) 0.13
Failure due to hematological toxicity, n (%) 10 (20.8) 8 (22.9) 1.00
Failure due to other toxicity, n (%) 6 (12.5) 3 (8.6) 0.73
Thirty-day reinfection, n (%) 3 (6.3) 2 (5.7) 1.00
Thrombocytopenia 15 (42.9) 11 (22.9) 0.060
  1. Abbreviations: TDM therapeutic drug monitoring, RI renal impairment